Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FP021
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
FP021 is a small molecule drug candidate described as a cyclooxygenase-2 (COX-2) inhibitor. Its mechanism of action involves selective inhibition of the COX-2 enzyme, which plays a key role in the inflammatory process by catalyzing the conversion of arachidonic acid to prostaglandins. By inhibiting COX-2, FP021 is expected to reduce inflammation and pain. The primary target for this compound is COX-2, and it falls within the class of nonsteroidal anti-inflammatory drugs (NSAIDs), specifically as a COX-2 selective inhibitor[1]. No additional information about its developer, manufacturer, or clinical development status was found in available sources.
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on FP021.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FP021.